Navigation Links
Is Chronic Pain Keeping You Awake? Help Is On the Way

WALTHAM, Mass., Oct. 22, 2013 /PRNewswire/ -- According to some studies, more than 100 million people in North America live with—or perhaps more accurately, don't find it easy to live with—days and nights filled with chronic pain. They know that persistent pain does more than make one achy and perhaps a bit cranky. Chronic pain has been associated with a significant increase in the rate of depression and anxiety. Most of those who have to endure chronic pain may also have problems with attention, memory, high blood pressure and related heart problems, along with sleep issues. Common causes of pain include degenerative spine disease, lower back pain, rheumatoid arthritis, osteoarthritis, fibromyalgia, HIV, migraine, neuropathy and complications of shingles.

This population includes approximately five million people with Type 2 diabetes who experience chronic pain, a condition called painful diabetic neuropathy (PDN). It is estimated that about half of them suffer pain that keeps them from getting to sleep, or when they do, staying asleep.   

Neuropathy in Type 2 diabetes can frustrate both patients and their doctors and other health providers. Although there is a range of treatments, including pharmaceutical painkillers, antidepressants, anticonvulsants, steroid and cortisone injections, analgesic patches, vitamin B shots and hot/cold packs, relief is often elusive or sporadic. People with chronic pain may need a deep, restorative night's rest to fully function.  

The good news is that there has been a major advance for PDN: the SENSUS Pain Management System. SENSUS has been developed by NeuroMetrix Inc., a medical device company in Waltham, Massachusetts. SENSUS offers transcutaneous electrical nerve stimulation and is the first device of its kind to receive 510(k) clearance from the U.S. Food and Drug Administration for use during sleep. SENSUS is lightweight, made to be worn under clothing, and offers non-narcotic pain relief as a complement to medications. It has an easy-to-use one-button control.

"At one time or another we all suffer from some level of pain. It is usually brief. Chronic pain is entirely different," says Shai N. Gozani, M.D., Ph.D., the President and CEO of NeuroMetrix. "It can result in sleep deprivation and interfere with relationships, work and overall well-being. We believe the SENSUS Pain Management System can make a difference to patients suffering from chronic pain, including PDN."

For more on SENSUS, visit or ask your doctor.

Contact: Laura Radocaj, Dian Griesel Int'l., 212.825.3210

SOURCE NeuroMetrix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
2. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
3. Aptel Research Launches Unique Patient-centric Syndicated Report Series That Analyze the Patient Journey for Chronic Diseases in Specialty Markets
4. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
5. Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
7. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
8. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
9. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
10. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
(Date:11/25/2015)... 2015 --> ... Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, welches ... innehaben, an Enyo Pharma vergeben haben. Im ... gerufenen und von Edelris gemeinsam mit seinen Partnern Inserm ... für HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, ...
(Date:11/24/2015)... , Nov. 25, 2015 WuXi PharmaTech ... ), a leading open-access R&D capability and technology platform ... with operations in China and ... that at an extraordinary general meeting of shareholders held ... proposal to authorize and approve the previously announced agreement ...
(Date:11/24/2015)... Nov. 24, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... New York.  The public is welcome to participate ... Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , ... 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 25, 2015 , ... ... Their Care Plan software creates an agreement between the practice owner and ... including financial, scheduling, monitoring, notification, and projections. Click here to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Charitable giving is at its peak during ... the last five weeks of the year totalling over $358 billion in 2014. ... the nation’s charities with those individuals who want to “give back” during the holidays. ...
(Date:11/24/2015)... ... 2015 , ... The hospitals and health systems on this ... care. They have received recognition for excellence from various reputable organizations in areas ... Hospital Review selected hospitals for inclusion based on national rankings and awards from ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
(Date:11/24/2015)... ... , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located ... the staff members at their recovery center. The videos highlight some of the various ... the things that make their recovery program so unique. , “Making the decision to ...
Breaking Medicine News(10 mins):